These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32047965)

  • 21. Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection.
    García-de-Lorenzo A; Luque S; Grau S; Agrifoglio A; Cachafeiro L; Herrero E; Asensio MJ; Sánchez SM; Roberts JA
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5914-21. PubMed ID: 27458229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial.
    Leroux S; Jacqz-Aigrain E; Elie V; Legrand F; Barin-Le Guellec C; Aurich B; Biran V; Dusang B; Goudjil S; Coopman S; Garcia Sanchez R; Zhao W; Manzoni P;
    Br J Clin Pharmacol; 2018 Sep; 84(9):1989-1999. PubMed ID: 29744900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic/Pharmacodynamic Target Attainment of Different Antifungal Agents in De-escalation Treatment in Critically Ill Patients: a Step toward Dose Optimization Using Monte Carlo Simulation.
    Xie J; Yang Q; Han X; Dong Y; Zhang T; Li Y; Ji M; Liu C; Cai Y; Wang Y
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0009922. PubMed ID: 35604209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis.
    Chen CY; Xie M; Gong J; Yu N; Wei R; Lei LL; Zhao SM; Li RM; Dong X; Zhang XL; Zhou Y; Li SL; Cui YM
    Front Pharmacol; 2023; 14():1132367. PubMed ID: 37188268
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacokinetics of Micafungin in Critically Ill Patients.
    Gastine S; Lanckohr C; Blessou M; Horn D; Fobker M; Bause D; Hempel G; Ellger B
    Sci Rep; 2019 Nov; 9(1):17741. PubMed ID: 31780687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Loading Dose of Caspofungin in Pharmacokinetic-Pharmacodynamic Target Attainment for Severe Candidiasis Infections in Patients in Intensive Care Units: the CASPOLOAD Study.
    Bailly S; Gautier-Veyret E; Lê MP; Bouadma L; Andremont O; Neuville M; Mourvillier B; Sonneville R; Magalhaes E; Lebut J; Radjou A; Smonig R; Wolff M; Massias L; Dupuis C; Timsit JF
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis.
    Muilwijk EW; Maertens JA; van der Velden WJFM; Ter Heine R; Colbers A; Burger DM; Andes D; Theunissen K; Blijlevens NMA; Brüggemann RJM
    J Antimicrob Chemother; 2018 Nov; 73(11):3095-3101. PubMed ID: 30137340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy and safety of colistimethate sodium in critical patients: an in vitro study by using of Monte Carlo simulation].
    Pan A; Mei Q; Yang T; Gao X; Lu H; Ye Y; Li J; Liu B
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 May; 29(5):385-389. PubMed ID: 28524024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
    Boonstra JM; van der Elst KC; Veringa A; Jongedijk EM; Brüggemann RJ; Koster RA; Kampinga GA; Kosterink JG; van der Werf TS; Zijlstra JG; Touw DJ; Alffenaar JWC
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterising the post-antifungal effects of micafungin against Candida albicans, Candida glabrata, Candida parapsilosis and Candida krusei isolates.
    Nguyen KT; Ta P; Hoang BT; Cheng S; Hao B; Nguyen MH; Clancy CJ
    Int J Antimicrob Agents; 2010 Jan; 35(1):80-4. PubMed ID: 19889519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating biapenem dosage regimens in intensive care unit patients with Pseudomonas aeruginosa infections: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
    Hang Y; Chen Y; Xue L; Sun S; Liu L; Gao J; Xie C; Zhang X; Zhu J; Jin J; Miao L
    Int J Antimicrob Agents; 2018 Mar; 51(3):484-487. PubMed ID: 28709989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration.
    Pérez-Pitarch A; Ferriols-Lisart R; Aguilar G; Ezquer-Garín C; Belda FJ; Guglieri-López B
    Int J Antimicrob Agents; 2018 Jan; 51(1):115-121. PubMed ID: 28666752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective Cohort Study of Micafungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-abdominal Infections.
    Garbez N; Mbatchi L; Wallis SC; Muller L; Lipman J; Roberts JA; Lefrant JY; Roger C
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0230720. PubMed ID: 33846133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure.
    Martial LC; Brüggemann RJ; Schouten JA; van Leeuwen HJ; van Zanten AR; de Lange DW; Muilwijk EW; Verweij PE; Burger DM; Aarnoutse RE; Pickkers P; Dorlo TP
    Clin Pharmacokinet; 2016 Jun; 55(6):723-33. PubMed ID: 26649870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
    Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
    J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetic model-guided optimization of intravenous voriconazole dosing regimens in critically ill patients with liver dysfunction.
    Lin XB; Lui KY; Guo PH; Liu XM; Liang T; Hu XG; Tong L; Wu JJ; Xia YZ; Chen P; Zhong GP; Chen X; Cai CJ
    Pharmacotherapy; 2022 Jan; 42(1):23-33. PubMed ID: 34655497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against Candida spp. and Aspergillus spp. in Allogeneic Stem Cell Transplant Recipients.
    Perez-Pitarch A; Guglieri-Lopez B; Ferriols-Lisart R; Pérez A; Ezquer-Garín C; Hernández-Boluda JC; Piñana JL; Navarro D; Solano C; Alós-Almiñana M
    Ther Drug Monit; 2019 Dec; 41(6):740-747. PubMed ID: 31136417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population Pharmacokinetics and Pharmacodynamics Modeling of Oral Levofloxacin.
    Jaruratanasirikul S; Jaspattananon A; Wongpoowarak W; Nawakitrangsan M; Thengyai S; Samaeng M
    J Med Assoc Thai; 2018 Aug; 99(8):886-92. PubMed ID: 29947489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of Micafungin Dosage Regimens in Patients with Cancer Using Pharmacokinetic/Pharmacodynamic Modeling and Monte Carlo Simulation.
    Alqahtani S; Alfarhan A; Alsultan A; Alsarhani E; Alsubaie A; Asiri Y
    Antibiotics (Basel); 2021 Nov; 10(11):. PubMed ID: 34827301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.